

(12)特許協力条約に基づいて公開された国際出願

改訂版

(19) 世界知的所有権機関
国際事務局



(43) 国際公開日
2002年7月11日 (11.07.2002)



PCT

(10) 国際公開番号
WO 02/053534 A1

- (51) 国際特許分類: C07D 209/42, 263/58, 401/12, 401/14, 403/06, 403/12, 413/12, 413/14, 417/06, 417/12, 471/04, 491/056, A61K 31/404, 31/423, 31/428, 31/439, 31/496, 31/454, 31/4725, 31/416, 31/5415, 31/437, 31/416, 31/5377, 31/427, 31/421, A61P 29/00, 37/06, 35/04, 11/06, 27/16, 3/10, 19/02, 17/06, 1/04
- (21) 国際出願番号: PCT/JP01/11641
- (22) 国際出願日: 2001年12月28日 (28.12.2001)
- (25) 国際出願の言語: 日本語
- (26) 国際公開の言語: 日本語
- (30) 優先権データ:
特願2000-402890 2000年12月28日 (28.12.2000) JP
特願2001-149923 2001年5月18日 (18.05.2001) JP
- (71) 出願人(米国を除く全ての指定国について): 第一製薬株式会社 (DAIICHI PHARMACEUTICAL CO., LTD.) [JP/JP]; 〒103-8234 東京都中央区日本橋3丁目14番10号 Tokyo (JP).
- (72) 発明者; および
(75) 発明者/出願人(米国についてのみ): 中山 敦
- (74) 代理人: 有賀 三幸, 外 (ARUGA,Mitsuyuki et al.); 〒103-0013 東京都中央区日本橋人形町1丁目3番6号共同ビル Tokyo (JP).
- (81) 指定国(国内): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, /統葉有]

(54) Title: VLA-4 INHIBITORS

(54) 発明の名称: VLA-4 阻害薬



WO 02/053534 A1

(57) Abstract: Compounds represented by the general formula (I) or salts thereof, and medicines containing the same: (I) [wherein W is $W^A-A^1-W^B$ - (wherein W^A is optionally substituted aryl or the like; A^1 is $-NR^{11}-$, a single bond, $-C(O)-$, or the like; and W^B is optionally substituted arylene or the like); R is a single bond, $-NH-$, $-OCH_2-$, alkylene, or the like; X is $-C(O)-$, $-CH_2-$, or the like; and M is, e.g., a group represented by the general formula (iii): (iii) (wherein R^{11} , R^{12} , and R^{13} are each independently hydrogen, hydroxyl, amino, halogeno, or the like; R^{14} is hydrogen or lower alkyl; Y is $-CH_2-O-$ or the like; Z is optionally substituted arylene or the like; A^2 is a single bond or the like; and R^{10} is hydroxyl or lower alkoxy)]. The compounds or the salts selectively inhibit the binding of cell adhesion molecules to VLA-4 and exhibit high oral absorbability, thus being useful as preventive and/or therapeutic drugs for inflammatory discases, autoimmune discases, cancerous metastasis, bronchial asthma, nasal occlusion, diabetes, and so on.

/統葉有]